Sweat no more: Botanix gears up for Sofdra debut
Botanix Pharmaceuticals (ASX:BOT), a clinical-stage dermatology company, recently shared its Q3 2024 update, focusing on preparations for the commercial launch of Sofdra, which is a new solution for excessive underarm sweating (an issue affecting roughly 10 million Americans). The drug, already FDA-approved, is set to hit the market in late Q4 2024. CEO Dr Howie […]
Sweat no more: Botanix gears up for Sofdra debut Read More »









